Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 6.37
ZGNX's Cash to Debt is ranked higher than
55% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. ZGNX: 6.37 )
Ranked among companies with meaningful Cash to Debt only.
ZGNX' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 1.75 Max: N/A
Current: 6.37
Equity to Asset 0.61
ZGNX's Equity to Asset is ranked lower than
54% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. ZGNX: 0.61 )
Ranked among companies with meaningful Equity to Asset only.
ZGNX' s Equity to Asset Range Over the Past 10 Years
Min: -3.87  Med: 0.16 Max: 0.61
Current: 0.61
-3.87
0.61
F-Score: 4
Z-Score: -0.76
M-Score: 1.05
WACC vs ROIC
10.55%
-82.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -163.67
ZGNX's Operating margin (%) is ranked lower than
91% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. ZGNX: -163.67 )
Ranked among companies with meaningful Operating margin (%) only.
ZGNX' s Operating margin (%) Range Over the Past 10 Years
Min: -299.29  Med: -161.13 Max: -49.44
Current: -163.67
-299.29
-49.44
Net-margin (%) 121.54
ZGNX's Net-margin (%) is ranked higher than
99% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.02 vs. ZGNX: 121.54 )
Ranked among companies with meaningful Net-margin (%) only.
ZGNX' s Net-margin (%) Range Over the Past 10 Years
Min: -313.81  Med: -223.29 Max: 21.19
Current: 121.54
-313.81
21.19
ROE (%) 28.03
ZGNX's ROE (%) is ranked higher than
91% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. ZGNX: 28.03 )
Ranked among companies with meaningful ROE (%) only.
ZGNX' s ROE (%) Range Over the Past 10 Years
Min: -491.54  Med: -419.76 Max: 23.3
Current: 28.03
-491.54
23.3
ROA (%) 14.40
ZGNX's ROA (%) is ranked higher than
89% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. ZGNX: 14.40 )
Ranked among companies with meaningful ROA (%) only.
ZGNX' s ROA (%) Range Over the Past 10 Years
Min: -164.96  Med: -86.09 Max: 5.45
Current: 14.4
-164.96
5.45
ROC (Joel Greenblatt) (%) -346.90
ZGNX's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.79 vs. ZGNX: -346.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ZGNX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -558.83  Med: -389.19 Max: 99.55
Current: -346.9
-558.83
99.55
Revenue Growth (3Y)(%) -31.80
ZGNX's Revenue Growth (3Y)(%) is ranked lower than
93% of the 605 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ZGNX: -31.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ZGNX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -31.10 Max: -31.8
Current: -31.8
» ZGNX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ZGNX Guru Trades in Q2 2015

Jim Simons 170,090 sh (New)
Paul Tudor Jones Sold Out
» More
Q3 2015

ZGNX Guru Trades in Q3 2015

Steven Cohen 3,800 sh (New)
Jim Simons 135,287 sh (+536.31%)
» More
Q4 2015

ZGNX Guru Trades in Q4 2015

Paul Tudor Jones 16,613 sh (New)
Jim Simons 136,887 sh (+1.18%)
Steven Cohen Sold Out
» More
Q1 2016

ZGNX Guru Trades in Q1 2016

Paul Tudor Jones 16,400 sh (-1.28%)
Jim Simons 74,087 sh (-45.88%)
» More
» Details

Insider Trades

Latest Guru Trades with ZGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:OTCPK:EUYNF, NAS:NBRV, NAS:OASM, NAS:ASMB, OTCPK:MBGRF, AMEX:NNVC, NAS:BITI, OTCPK:BIOYF, NAS:ALIM, OTCPK:PMXSF, NAS:NTEC, AMEX:AXN, NAS:TNXP, NAS:NVGN, NAS:ALQA, OTCPK:NNAB, OTCPK:SUWN, NAS:RMTI, NAS:PRPH, NAS:ECTE » details
Traded in other countries:Z081.Germany,
Zogenix Inc is a pharmaceutical company engaged in commercializing & developing therapies that address clinical needs for people living with pain-related and CNS disorders that needs treatment alternatives to help return to normal daily functioning.

Zogenix Inc was formed as a Delaware Corporation on May 11, 2006. The Company is a pharmaceutical company that develops and commercializes therapies that address specific needs for people living with pain-related conditions and central nervous system disorders who needs treatment alternatives to help them return to normal daily functioning. The Company's first commercial product, Sumavel DosePro Needle-free Delivery System, was launched in January 2010. Sumavel DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Sumavel DosePro is the first drug product approved by the U.S. Food and Drug Administration, or FDA that allows for the needle-free, subcutaneous delivery of medication. Sumavel DosePro may offer a faster-acting and more efficacious treatment alternative to oral and nasal triptans and simple, convenient administration when compared to traditional, needle-based sumatriptan injection. The Company's main product candidate, Zohydro ER, is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. The Company also develops Relday, a proprietary, long-acting injectable formulation of risperidone using Durect Corporation's SABER controlled-release formulation technology through a development and license agreement with Durect Corporation. The Company's competitors include: AstraZeneca plc, Endo Pharmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., and Pfizer, Inc. In the United States, pharmaceutical products are subject to extensive regulation by the FDA. Its trademarks include DosePro, Relday, Zogenix and Zohydro ER. The Company is subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or FFDCA, and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Ratios

vs
industry
vs
history
P/E(ttm) 3.46
ZGNX's P/E(ttm) is ranked higher than
97% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.34 vs. ZGNX: 3.46 )
Ranked among companies with meaningful P/E(ttm) only.
ZGNX' s P/E(ttm) Range Over the Past 10 Years
Min: 0.05  Med: 9.33 Max: 168
Current: 3.46
0.05
168
Price/Owner Earnings (ttm) 14.52
ZGNX's Price/Owner Earnings (ttm) is ranked higher than
81% of the 267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.00 vs. ZGNX: 14.52 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ZGNX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 14.35  Med: 26.03 Max: 53.1
Current: 14.52
14.35
53.1
P/B 1.15
ZGNX's P/B is ranked higher than
82% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. ZGNX: 1.15 )
Ranked among companies with meaningful P/B only.
ZGNX' s P/B Range Over the Past 10 Years
Min: 1.15  Med: 5.81 Max: 543.53
Current: 1.15
1.15
543.53
P/S 5.63
ZGNX's P/S is ranked lower than
72% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. ZGNX: 5.63 )
Ranked among companies with meaningful P/S only.
ZGNX' s P/S Range Over the Past 10 Years
Min: 0.3  Med: 4.96 Max: 14.79
Current: 5.63
0.3
14.79
EV-to-EBIT -1.72
ZGNX's EV-to-EBIT is ranked lower than
99.99% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.96 vs. ZGNX: -1.72 )
Ranked among companies with meaningful EV-to-EBIT only.
ZGNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.8  Med: -2.60 Max: 8.4
Current: -1.72
-9.8
8.4
EV-to-EBITDA -1.78
ZGNX's EV-to-EBITDA is ranked lower than
99.99% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.28 vs. ZGNX: -1.78 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZGNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.1  Med: -2.80 Max: 8
Current: -1.78
-10.1
8
Current Ratio 7.87
ZGNX's Current Ratio is ranked higher than
87% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. ZGNX: 7.87 )
Ranked among companies with meaningful Current Ratio only.
ZGNX' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.69 Max: 7.87
Current: 7.87
0.85
7.87
Quick Ratio 7.41
ZGNX's Quick Ratio is ranked higher than
86% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. ZGNX: 7.41 )
Ranked among companies with meaningful Quick Ratio only.
ZGNX' s Quick Ratio Range Over the Past 10 Years
Min: 0.32  Med: 1.41 Max: 7.41
Current: 7.41
0.32
7.41
Days Inventory 158.13
ZGNX's Days Inventory is ranked lower than
71% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.06 vs. ZGNX: 158.13 )
Ranked among companies with meaningful Days Inventory only.
ZGNX' s Days Inventory Range Over the Past 10 Years
Min: 122.4  Med: 255.05 Max: 419.33
Current: 158.13
122.4
419.33
Days Sales Outstanding 56.33
ZGNX's Days Sales Outstanding is ranked higher than
66% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.75 vs. ZGNX: 56.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.47  Med: 54.74 Max: 73.69
Current: 56.33
46.47
73.69
Days Payable 47.81
ZGNX's Days Payable is ranked lower than
71% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.79 vs. ZGNX: 47.81 )
Ranked among companies with meaningful Days Payable only.
ZGNX' s Days Payable Range Over the Past 10 Years
Min: 54.3  Med: 80.39 Max: 148.78
Current: 47.81
54.3
148.78

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.32
ZGNX's Price/Net Cash is ranked higher than
55% of the 211 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.34 vs. ZGNX: 10.32 )
Ranked among companies with meaningful Price/Net Cash only.
ZGNX' s Price/Net Cash Range Over the Past 10 Years
Min: 9.25  Med: 11.85 Max: 153.33
Current: 10.32
9.25
153.33
Price/Net Current Asset Value 3.96
ZGNX's Price/Net Current Asset Value is ranked higher than
71% of the 438 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.67 vs. ZGNX: 3.96 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ZGNX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.95  Med: 5.51 Max: 22.24
Current: 3.96
3.95
22.24
Price/Tangible Book 3.06
ZGNX's Price/Tangible Book is ranked higher than
55% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. ZGNX: 3.06 )
Ranked among companies with meaningful Price/Tangible Book only.
ZGNX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.82  Med: 7.99 Max: 470.59
Current: 3.06
2.82
470.59
Price/Median PS Value 1.25
ZGNX's Price/Median PS Value is ranked lower than
62% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. ZGNX: 1.25 )
Ranked among companies with meaningful Price/Median PS Value only.
ZGNX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.1  Med: 1.02 Max: 2.53
Current: 1.25
0.1
2.53
Earnings Yield (Greenblatt) (%) -58.20
ZGNX's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ZGNX: -58.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ZGNX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 11.9  Med: 24.90 Max: 20885.2
Current: -58.2
11.9
20885.2

More Statistics

Revenue (TTM) (Mil) $31.77
EPS (TTM) $ 2.35
Beta1.19
Short Percentage of Float20.28%
52-Week Range $7.33 - 21.65
Shares Outstanding (Mil)24.77

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 22 18 22
EPS ($) -3.27 -2.93 -2.56
EPS w/o NRI ($) -3.27 -2.93 -2.56
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for ZGNX

Headlines

Articles On GuruFocus.com
Analysts Weigh in on Zogenix in Light of Selling Zohydro Mar 12 2015 
Weekly CFO Buys Highlight: NGL, UNTK, ZGNX, VTSS, RVSB Dec 24 2012 
(ZGNX) CEO Roger Hawley buys 10,000 Shares Dec 06 2010 

More From Other Websites
Zogenix Announces Agreement to Refinance Debt, Further Increasing Company’s Expected 2017 Cash... Jun 21 2016
Zogenix Announces Agreement to Refinance Debt, Further Increasing Company’s Expected 2017 Cash... Jun 21 2016
ZOGENIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jun 21 2016
Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome Jun 07 2016
ZOGENIX, INC. Files SEC form 8-K, Other Events Jun 07 2016
Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome Jun 07 2016
Zogenix to Participate in Jefferies 2016 Healthcare Conference May 31 2016
Zogenix to Participate in Jefferies 2016 Healthcare Conference May 31 2016
ETF’s with exposure to Zogenix, Inc. : May 24, 2016 May 24 2016
Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 May 23 2016
ZOGENIX, INC. Financials May 19 2016
Zogenix reports 1Q loss May 10 2016
Zogenix reports 1Q loss May 10 2016
ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 10 2016
Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results May 10 2016
Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results May 10 2016
Q1 2016 Zogenix Inc Earnings Release - After Market Close May 10 2016
ZOGENIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement May 05 2016
Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome May 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)